Submit your email to push it up the queue
Bayer HealthCare Pharmaceuticals Inc., a prominent division of Bayer AG, is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 1863, the company has established itself as a leader in the pharmaceutical industry, focusing on areas such as cardiology, oncology, gynaecology, and ophthalmology. Bayer HealthCare is renowned for its innovative products, including prescription medications and over-the-counter solutions that address critical health needs. Its commitment to research and development has led to significant advancements in treatment options, setting it apart in a competitive market. With a strong market position, Bayer HealthCare has achieved numerous accolades for its contributions to healthcare, underscoring its role as a trusted provider of effective and safe pharmaceutical solutions.
How does Bayer HealthCare Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Bayer HealthCare Pharmaceuticals Inc.'s score of 90 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Bayer HealthCare Pharmaceuticals Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Bayer Aktiengesellschaft, which cascades its climate commitments and emissions data down to its subsidiaries. Bayer Aktiengesellschaft has set ambitious climate targets, including commitments to reduce emissions across its operations. However, specific reduction targets or achievements for Bayer HealthCare Pharmaceuticals Inc. have not been detailed. The company is aligned with various climate initiatives, including the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are managed at the parent company level. As part of its corporate family, Bayer HealthCare Pharmaceuticals Inc. benefits from the overarching sustainability strategies of Bayer Aktiengesellschaft, which include efforts to address Scope 1, 2, and 3 emissions. While specific figures for Bayer HealthCare Pharmaceuticals Inc. are not available, the commitment to sustainability and climate action remains a priority within the organisation.
Access structured emissions data, company-specific emission factors, and source documents
2006 | 2007 | 2008 | 2009 | 2010 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 5,710,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Scope 2 | 3,670,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Scope 3 | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bayer HealthCare Pharmaceuticals Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.